AC Immune (ACIU) announced the appointment of Prof. Catherine Mummery, a deeply experienced neurologist and expert in dementia clinical trials, as Chairwoman of its Clinical Advisory Board, CAB. Prof. Mummery leads the cognitive disorders service at the UK’s National Hospital for Neurology and Neurosurgery, where she has practiced as a consultant neurologist since 2004.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACIU:
- AC Immune’s ACI-24.060 Study: A Potential Game-Changer in Alzheimer’s Treatment
- AC Immune’s Innovative PET Tracer Study: A Potential Game-Changer for Neurodegenerative Diagnostics
- AC Immune’s Innovative PET Radioligand Study: A Potential Game-Changer in Neurodegenerative Diagnostics
- AC Immune SA: Pioneering Innovations in Neurodegenerative Disease Treatment and Diagnostics
- AC Immune announces publication of preclinical data on ACI-19626